Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.75 |
| ▸ | ERBB2 | P04626 | 17/20 | 0.75 |
| ▸ | GAK | O14976 | 1/20 | 0.55 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.54 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4480888 | 0.92 | EGFR (0.63) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL3807553 | 0.89 | ERBB2 (0.65) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL3807511 | 0.89 | EGFR (0.66) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL4480561 | 0.87 | ERBB2 (0.76) | EGFRERBB2GAK | |
| SCHEMBL1406407 | 0.87 | ERBB2 (0.65) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL3815330 | 0.87 | EGFR (0.65) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL4478540 | 0.85 | ERBB2 (1.00) | EGFRERBB2 | |
| Trifluoroacetic Acid SCHEMBL3816939 | 0.85 | EGFR (0.58) | EGFRERBB2GAKERBB4ERBB3 | |
| SCHEMBL4480720 | 0.85 | ERBB2 (0.82) | EGFRERBB2 | |
| SCHEMBL4469684 | 0.85 | ERBB2 (0.74) | EGFRERBB2ERBB4ERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625908-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | claimed |
| US-20070244136-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | claimed |
| JP-2007511491-A | — | — | 2007-05-10 | — | — | JP | claimed |
| EP-1685116-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | claimed |
| WO-2005051923-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-06-09 | — | — | WO | claimed |
| US-7625908-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-20070244136-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| EP-1685116-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005051923-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244136-A1 | Quinazoline Derivatives | ERBB2, ABL1, MKI67 | EGFR 10/4885ERBB2 1/4885GAK 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.